Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Cyto Pulse, the Karolinska Institute and Uppsala University Hospital Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Using a Xenogenic PSA DNA Vaccine
- GLEN BURNIE, Md. -- Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval by Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with recurring prostate cancer. The trial will investigate the safety of a xenogenic...
- Research articles 2008-10-10
- Advaxis Incorporated Collaborates on Groundbreaking Listeria Moncoytogenes Immunotherapy Research Discovery
- Highlights Potential Ability of a Live Listeria Monocytogenes Vaccine to Reduce/Eliminate Tumors in Many Different Cancer Types and Prevent Reoccurrence Using Immunological Methods Collaboration Team Comprised of Advaxis' Scientific Founder, And Investigators From The University Of Pennsylvania And The Hilman Cancer Center In Pittsburgh NORTH BRUNSWICK, N.J. --...
- Research articles 2008-10-07
- Advaxis Chief Executive Officer to Present at the 10th Annual World Vaccine Congress
- Presentations to Address Challenges Facing Biotech Companies and the use of Bacterial Vectors for The Treatment of Cancer Conference to be Held October 6-9, 2008, at Le Palais des Congres de Lyon, France NEW BRUNSWICK, N.J. -- Advaxis Incorporated (OTCBB: ADXS) Chairman and CEO Tom Moore will present...
- Research articles 2008-10-06
- U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million
- New Contract Extends USG's Commitment to Purchase BioThrax Through 3Q 2011 and is a Follow-on to the Existing 2007, $448 Million Contract ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and...
- Research articles 2008-10-01
- Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine
- --AV7909 Contract is in Addition to Recently Announced $24 Million Development Contract for Anthrax Monoclonal and Pending Proposal to Supply HHS with Up to 25 Million Doses of a Recombinant Anthrax Vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with BARDA/NIAID,...
- Research articles 2008-09-26
- Scottish schoolgirls get cancer jab
- LONDON AFP — Schoolgirls in Scotland became the first in the country to get a jab against cervical cancer on Monday. Pupils aged 12 and 13 in several areas are being offered the vaccine from this week, as part of a nationwide programme announced last October. The programme...
- Research articles 2008-09-01
- The Daily Record News Briefs: August 27, 2008
- Bay Bridge traffic alert! The Maryland Transportation Authority said it has closed a lane of the Chesapeake Bay Bridge to install safety measures following a fatal accident earlier this month. The closure of the right lane of the eastbound span will remain in effect for the next two...
- Research articles 2008-08-27
- Authorities drop legal bid to force baby's vaccination
- SYDNEY AFP — Australian child welfare authorities on Tuesday ended a legal bid to force a couple to vaccinate their six-day-old baby against hepatitis B after the family went into hiding, authorities said. The New South Wales Department of Community Services decided to drop its pursuit of the couple...
- Research articles 2008-08-26
- Couple in hiding with 2-day-old son to avoid vaccination: report
- SYDNEY AFP — A couple have fled their home in Australia and gone into hiding with their two-day-old son to avoid having him forcibly vaccinated against hepatitis B, a report said on Saturday. The family, including the boy's mother who was diagnosed with hepatitis B several years ago, went...
- Research articles 2008-08-22
- ASU's Biodesign Institute and ImmuneRegen Collaborate to Investigate Possible Enhancement of Vaccine Against Norwalk Viruses
- ImmuneRegen ® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announced a collaborative relationship with the Biodesign Institute at Arizona State University ASU, Tempe, Ariz., to evaluate the effectiveness of ImmuneRegen's Viprovex ® in boosting the immune response when...
- Research articles 2008-08-18
- In the lab, Ivins used different kind of anthrax
- The death of government scientist Bruce Ivins, a new focus of the investigation into the 2001 anthrax attacks, revives old questions about anthrax and adds new ones. USA TODAY reporters Dan Vergano and Steve Sternberg provide a sampling: Q: What is anthrax? ...
- Research articles 2008-08-04
- Suspect in anthrax case kills himself before arrest
- WASHINGTON -- Federal agents were closing in, and Bruce Ivins knew it. The Army microbiologist who was working on a vaccine for anthrax poisoning was now being grilled as a suspect in the 2001 letter attacks that killed five people and sickened 17. FBI agents were staking out...
- Research articles 2008-08-02
- Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
- The company's submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted a proposal in response to a request for proposal...
- Research articles 2008-07-31
- GenVec Receives Continued Funding from the U.S. Department of Homeland Security for Vaccine Program
- GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC) announced today that the U.S. Department of Homeland Security DHS has executed the second option period under a three-year agreement with GenVec to support the development of vaccines for the prevention of foot-and-mouth disease FMD. GenVec will receive up to $6.6 million to complete...
- Research articles 2008-07-29
- Kidney cancer vaccine falls short in clinical trial: study
- PARIS AFP — A new kidney cancer vaccine failed in last-phase clinical trials to improve the odds of avoiding remission after tumour-removing surgery, according to a study released Friday. A team of researchers led by Christopher Wood of the Anderson Cancer Center in Houston, Texas gave the vaccine, called...
- Research articles 2008-07-03
- Diagnostic HYBRIDS Receives Third Frontier Grant for Development of Assays to Monitor Drug Resistance and Vaccine Production
- ATHENS, Ohio -- Diagnostic HYBRIDS has received funding through the Biomedical Research Commercialization Program BRCP to develop more sensitive and affordable assays for the monitoring of patients infected with Human Immunodeficiency Virus HIV and/or Hepatitis C Virus HCV and to produce vaccines against influenza virus. The BRCP is part of...
- Research articles 2008-06-27
- Medicago CEO to Participate in Panel Discussion at the World Vaccine Congress Asia 2008
- Medicago Inc. (TSX VENTURE: MDG) (the "Company"), today announced that Mr. Andy Sheldon, President and CEO, will participate in a panel discussion entitled "Addressing the limited global capacity in producing pandemic and seasonal flu vaccines" at the World Vaccine Congress Asia 2008. The conference will be held at the Grand...
- Research articles 2008-06-02
- Vaccine test marks rise of commercial research in space: NASA
- CAPE CANAVERAL, Florida AFP — An experiment to develop a salmonella vaccine aboard the US space shuttle Discovery could pave the way for a gush of commercial biotechnology research in space, NASA and biotech industry officials said Friday. Executives of Spacehab Inc. said that if the company's research on...
- Research articles 2008-05-30
- Swiss company says malaria vaccine tests 'successful'
- NYON AFP — A Swiss biotechnology company said Wednesday that it has successfully tested a malaria vaccine which could be marketed as early as 2014, according to a statement from directors. Mymetics, who acquired the trial vaccine from Swiss research and development company Pevion Biotech, said it had carried...
- Research articles 2008-05-28
- China in emergency vaccination drive in quake-hit areas
- BEIJING AFP — China said Tuesday it would provide mass emergency vaccinations in quake-hit areas to curb potential epidemics, but reported no major disease outbreaks so far. "By June 15, emergency inoculation of vulnerable people will be completed including vaccines against Hepatitis A and Encephalitis B," Sun Jiahai, a...
- Research articles 2008-05-27
- << Previous
- page 1 of 76
- Next >>
Content Types
Refining Tags
- Healthcare (1,006 results)
- Agence France-Presse (198 results)
- Government (132 results)
- Software (131 results)
- U.S. Department Of Health And Human Services (115 results)
- Finance (104 results)
- Merck & Co. Inc. (104 results)
- FDA (104 results)
- Benefits (101 results)
- Nasdaq Stock Market Inc. (100 results)
- Virus (94 results)
- SECURITY (88 results)
- U.S. Department of Defense (83 results)
- stock (72 results)
- Company (71 results)
- World Health Organization (52 results)
- Biotechnology (51 results)
- Investment (50 results)
- Influenza (45 results)
- Patient (44 results)
- U.S. Congress (44 results)
- U.S. (43 results)
- Chiron Corp. (41 results)
- Manufacturing (38 results)
- Pentagon (38 results)
- cell (35 results)
- Marketing (34 results)
- outbreak (33 results)
- Dr. (32 results)
- Nigeria (32 results)
- Sales (29 results)
- patent (28 results)
- GlaxoSmithKline Plc. (27 results)
- SEC (25 results)
- agreement (25 results)
- NYSE Euronext (24 results)
- president (23 results)
- Infection (22 results)
- China (21 results)
- attack (21 results)
- protein (21 results)
- financial (21 results)
- Boston Globe (21 results)
- U.S. Senate (21 results)
- U.S. Department of Agriculture (21 results)
- U.S. Government (19 results)
- DNA (19 results)
- Researcher (18 results)
- White House (18 results)
- investor (18 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
